Navigation Links
ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data,Presented at International Myeloma Workshop

KOS, Greece--(BUSINESS WIRE)--Jun 28, 2007 - ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today the presentation of two posters at the XIth Annual International Myeloma Workshop being held in Kos, Greece from June 25-28th, 2007. The meeting highlights important advances made in the biology and treatment of multiple myeloma. ZIOPHARM is presenting darinaparsin (ZIO-101) gene expression profiling data that further elucidates its unique mechanism of action as well as interim Phase II data from two ongoing trials in advanced myeloma.

The first poster, presented on Tuesday June 26th by Larry Boise, PhD from the Sylvester Comprehensive Cancer Center at the University of Miami highlighted preclinical data demonstrating darinaparsin (ZIO-101) may have activity in myeloma patients who have already been treated with and no longer respond to arsenic trioxide.

The second poster, presented today by James R. Berenson, M.D., Berenson Oncology, Inc., West Hollywood, CA, and principal investigator, reiterates interim phase II data from two ongoing studies recently presented at the American Society of Clinical Oncology (ASCO) Meeting in Chicago. The two ongoing phase II studies are evaluating the preliminary efficacy and safety profile of different treatment schedules (5 consecutive days every four weeks; twice weekly for 3 weeks, every four weeks) in patients with advanced/progressive myeloma (patients to date have had a median of 7 prior therapies). As reported, of the 14 patients treated 5 consecutive days, there are 10 patients evaluable for efficacy, with 4 out of the 10 (40%) achieving stable disease greater than 4 months duration. Data from the twice weekly study is not yet evaluable (3 patients treated). Darinaparsin has been well tolerated and no clinically relevant QT prolongation, bone marrow suppression or neuropathy has been observed with either treatment schedule.

"With the passage of time it bec
'"/>




Page: 1 2 3 4

Related medicine technology :

1. ZIOPHARM Presents Data Highlighting Oral ZIO-101 at AACR
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:8/28/2014)... Aug. 28, 2014 Levi & Korsinsky announces ... the United States District Court for the District of ... who purchased Galectin Therapeutics Inc. ("Galectin" or the "Company") ... 28, 2014. For more information, click here: ... during the Class Period the Company violated federal securities ...
(Date:8/28/2014)... , August 28, 2014 ... titled, "DNA diagnostics Market (products, applications, techniques, end ... Opportunities, Growth and Forecast, 2013 - 2020," indicates ... $19 billion by 2020 registering a CAGR of ... provide accurate diagnosis and cost effectiveness over alternative ...
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- Gateway Analytical announced ... 9 th Annual Global Pharma Manufacturing Summit ... 8-9 th . The Global Pharma Manufacturing Summit ... small molecule and biologic pharmaceutical manufacturing. The conference ... today,s manufacturers face, such as the increasing pressure ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3
... -- China Health Resource, Inc. (OTCBB: CHRI), today announced results ... the first quarter of 2012. Revenues for ... increase of 234% over revenues of US $10,282,207 for 2010. For ... common share, compared with a net income of $2,707,286, or ...
... Oncos Therapeutics today announced the successful initiation ... adenovirus suggested as a potential new treatment for many types ... safety assessment part of the study. " We ... r thern Europe to start a clinical study with ...
Cached Medicine Technology:China Health Resource Reports on Record Year-End 2011 Results Continuing Strong in 2012 2China Health Resource Reports on Record Year-End 2011 Results Continuing Strong in 2012 3Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers 2
(Date:8/29/2014)... 29, 2014 Top10BestSEOHosting.com today compares ... USA and announces that Bluehost ( http://www.bluehost.com/track/seohosts ), ... hosting companies for webmasters who want to buy ... cloud hosting) at affordable rates. , Bluehost is ... One of its features is that Bluehost provides ...
(Date:8/29/2014)... The Department of Health and Human ... for Food Safety and Applied Nutrition (CFSAN), awarded ... contract and the first two task orders: “FARM ... Enhancement (DME) for FARM VI” to the team ... objectives include:, ,     Upgrade FARM platform ...
(Date:8/29/2014)... Two Kelowna dentists are putting out a ... container filled with classroom materials, clinic supplies and even two ... , “I don’t think words can describe what ... She and her husband, Dr. Jonathan Visscher, both partners at ... of New Reality International’s (NRI) mission to build and raise ...
(Date:8/28/2014)... 2014 When David Gergen, President of ... of Mark Brnovich, was asked to publicly support Mr. ... the Attorney General seat in the State of Arizona, ... support of Cardinal Hall of Fame wide receiver Roy ... and Mark Walczak. Green, Kennard and Walczak are members ...
(Date:8/28/2014)... 2014 Starting on Monday, the ... to accept donations in Bitcoin, in addition to all ... can be found at http://www.curemeso.org/bitcoin . , ... a form of payment, we decided it was important ... chief executive officer, Melinda Kotzian. , Bitcoin is ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: Bluehost, Arvixe, and Hostgator Are the Best Windows Web Hosting from the USA in 2014 2Health News:Team VersaTech and CRGT Win HHS FDA Contract to Support Food Applications Regulatory Management (FARM) System Upgrade 2Health News:Team VersaTech and CRGT Win HHS FDA Contract to Support Food Applications Regulatory Management (FARM) System Upgrade 3Health News:From Canada to Haiti: Kelowna Dentists Raise Funds to Ship Supplies to Self-Sustaining Village for Orphans 2Health News:From Canada to Haiti: Kelowna Dentists Raise Funds to Ship Supplies to Self-Sustaining Village for Orphans 3Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:Cancer Research Funding Organization Now Accepts Bitcoin Donations 2
... (HealthDay News) -- Researchers have identified five new genes that ... coronary artery disease -- the most common cause of premature ... study. The international consortium said their discovery could ... treatments for the condition. In conducting the study, published ...
... Disease Alliance (ECDA)1 welcomes the UN High Level Meeting on ... "It is a memorable day in the history of ... gives a strong sense of the burden it represents to ... for all nations in the world2", declared Professor Michel Komajda, ...
... FRIDAY, Sept. 23 (HealthDay News) -- In large and diverse ... stick together, establishing both friendships and romantic relationships with ... people have in who they become close to, the researchers ... prefer to make friends with others who are similar to ...
... 22 (HealthDay News) -- A cardiac rehabilitation program appeared ... second stroke among patients who have suffered mild strokes ... researchers have found. "Overall, following the cardiac rehab ... in their risk profile," study senior investigator Neville Suskin, ...
... calcium-sensitizing drug levosimendan may be effective in improving ... which often accompanies chronic diseases such as chronic ... according to researchers in the Netherlands, who studied ... The drug, which is normally prescribed in patients ...
... , THURSDAY, Sept. 22 (HealthDay News) -- A new ... develop acute leukemia than whites. But if they do become ... know the reason for the disparity, but now that we ... study lead researcher Dr. Manali I. Patel, postdoctoral fellow in ...
Cached Medicine News:Health News:Scientists ID More Genes Linked to Heart Disease 2Health News:Non-communicable diseases at the center of UN discussions 2Health News:People Tend to Choose Friends Just Like Themselves 2Health News:Cardiac Rehab May Cut Risk Factors After Mini-Stroke 2Health News:Heart drug offers possible treatment for patients facing respiratory failure 2Health News:Heart drug offers possible treatment for patients facing respiratory failure 3Health News:Death Rate Higher in Minorities With Acute Leukemia 2
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
Interseal acetabular cup system addresses the contemporary issues of the two-piece cementless acetabular component design....
... Alfa acetabular cup system has been designed ... a tri-spiked and cluster hole configurations. The ... minimize micromotion on three primary modes: Tilt, ... design features result in initial and long-term ...
Optimal solution for normal acetabulum....
Medicine Products: